Researchers have been looking for insulin-stimulating factors for more than 100 years, and
in the 1960ties it was definitively proven that the gastrointestinal tract releases important …

Objective The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-
dependent insulinotropic peptide) are secreted by the gut after food intake leading to …

Abstract Purpose of Review To discuss evidence supporting the use of glucagon-like
peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective …

Activation of the GLP-1-dependent pathways may perhaps translate into a lower
cardiovascular risk. Understanding how GLP-1 and GLP-2 regulate and interact in the …

Abstract Glucagon-like peptide-1 (GLP-1) is an incretin secreted in response to nutrient
ingestion. Understanding the incretin effect on diabetes pathophysiology has led to …

Type 2 diabetes mellitus is a major and growing health problem throughout the world.
Current treatment approaches include diet, exercise, and a variety of pharmacological …

Abstract Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, secreted in
response to ingestion of nutrients, and has important effects on several of the …

Glucagon like peptide-1 (GLP-1) receptor agonists are well established drugs for the
treatment of type 2 diabetes (T2D). In addition to glycemic control, GLP-1 receptor agonists …

The growing global burden of type 2 diabetes mellitus confers significant morbidity and
mortality in addition to significant cost to local health-care systems. In recent years, 2 classes …

Obesity and type 2 diabetes mellitus (T2DM) are widespread, non-communicable diseases
that are responsible for considerable levels of morbidity and mortality globally, primarily in …